Newamsterdam Pharma Co Nv earnings were -$250.3M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest NAMS earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$55.7M, down 36.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NAMS reported annual earnings of -$239.8M, with -4.7% growth.
Newamsterdam Pharma Co Nv Earnings Reports & History FAQ
What were Newamsterdam Pharma Co Nv's earnings last quarter?
On NAMS's earnings call on Invalid Date, Newamsterdam Pharma Co Nv (NASDAQ: NAMS) reported Q1 2026 earnings per share (EPS) of -$0.46, up 24.32% year over year. Total NAMS earnings for the quarter were -$55.68 million. In the same quarter last year, Newamsterdam Pharma Co Nv's earnings per share (EPS) was -$0.37.
Is Newamsterdam Pharma Co Nv profitable or losing money?
As of the last Newamsterdam Pharma Co Nv earnings report, Newamsterdam Pharma Co Nv is currently losing money. Newamsterdam Pharma Co Nv's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$244.52 million, a 20.07% increase year over year.
What was NAMS's earnings growth in the past year?
As of Newamsterdam Pharma Co Nv's earnings date in Invalid Date, Newamsterdam Pharma Co Nv's earnings has grown year over year. NAMS earnings in the past year totalled -$250.27 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.